A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Genentech, Inc.
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Translational Oncology Research International
NYU Langone Health
Centro Nacional de Investigaciones Oncologicas CARLOS III
OHSU Knight Cancer Institute
Dana-Farber Cancer Institute
Austin Health
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute